Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluation of Adjuvant Nivolumab in Patients with Resected Stage III–IV Melanoma: Two-Year Findings from the AdjuMel Study

  • By

  • Stéphane Dalle

  • Philippe Saiag

  • Céleste Lebbé

  • Jean-Jacques Grob

  • Brigitte Dréno

  • Sophie Dalac

  • Bernard Asselain

  • François Skowron

  • Sophie Darras

  • Nicolas Jovenin

  • Gaëlle Quereux

  • Amir Khammari

  • Capucine Rieuf

  • Florence Brellier

  • Laurent Mortier

  • August 29, 2026

Share

  • 1

    Nivolumab is an approved adjuvant treatment for patients with completely resected stage III–IV melanoma, addressing rising mortality rates in Europe.

  • 2

    The AdjuMel study evaluates real-world use, effectiveness, and safety of adjuvant nivolumab in patients with resected stage III–IV melanoma in France.

  • 3

    At 2 years, relapse-free survival for patients in the study reached 52.8%, with lower recurrence rates in stage IIIA compared to IIIB–D.

  • 4

    Tumor ulceration was linked to a higher risk of recurrence or death, while age also influenced outcomes, with younger patients faring better.

  • 5

    The safety profile of adjuvant nivolumab remained consistent with previous reports, showing no adverse effects on health-related quality of life.

Original Source(s)

Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel

  • by Stéphane Dalle, Philippe Saiag, Céleste Lebbé, Jean-Jacques Grob, Brigitte Dréno, Sophie Dalac, Bernard Asselain, François Skowron, Sophie Darras, Nicolas Jovenin, Gaëlle Quereux, Amir Khammari, Capucine Rieuf, Florence Brellier, Laurent Mortier

  • August 29, 2026

Related Content

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • by

  • August 26, 2026

  • 5 min
Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas